# Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

> **NCT00877110** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 71 (actual)

## Conditions studied

- Neuroblastoma
- Bone Marrow, Sympathetic Nervous System

## Interventions

- **DRUG:** cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

## Key facts

- **NCT ID:** NCT00877110
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-02
- **Primary completion:** 2019-01-07
- **Final completion:** 2019-01-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00877110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00877110, "Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00877110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*